International reference pricing proposals currently under consideration by the U.S. Congress, and proposed in the previous Congress as Title I of H.R. 3, would allow federal government use of foreign price controls in direct negotiations with pharmaceutical companies for the cost of 250 prescription medicines in Medicare Part B and Part D. It also extended the negotiated price to insurers and the commercial market at large.
Given the risks of investing in medical breakthroughs for neurological conditions, companies need successful products to underwrite and subsidize the investment into new areas of this research. A new analysis by Vital Transformation and the Alliance for Aging Research shows that implementing international reference pricing in the U.S. would decimate the clinical development of therapies for Alzheimer’s disease and related dementias and drastically reduce the revenue that helps support this critical research.
In this special bonus episode, Alliance President and CEO Sue Peschin discusses this analysis with Vital Transformation’s Managing Director Duane Schulthess.
Read the full report here: https://www.agingresearch.org/press-release/new-analysis-shows-international-reference-drug-pricing-would-have-a-catastrophic-impact-on-alzheimers-disease-research/
Listen and subscribe to This is Growing Old:
Apple Podcasts: https://podcasts.apple.com/us/podcast/this-is-growing-old/id1515752172
Google Podcasts:
https://www.google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy8yMjA1ZjQ3MC9wb2RjYXN0L3Jzcw==
Spotify: https://open.spotify.com/show/1Zm5NELpFctDTQjNzT7Tfo
source
